Position in EXEL
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$1,715,547
+$60,465 QoQ
Shares Held
31,530
-18.3% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#277
of 751 holders
Holding Since
Dec 2024
7 quarters on record
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Kestra Investment Management, LLC holds $5,070,571 across 6 Biotechnology names. EXEL ranks #1 (33.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
31,530 | $1,715,547 | |
| 2 | INCY |
Incyte Corp
|
12,148 | $1,377,097 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,618 | $788,096 | |
| 4 | RPRX |
Royalty Pharma plc
|
7,788 | $436,673 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
659 | $410,912 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
689 | $342,246 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,715,547 | 31,530 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $1,655,082 | 38,589 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,255,860 | 28,653 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $1,142,812 | 27,671 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $888,432 | 20,155 | Shares | Sole | 2025-08-15 | |
| 2025-03-31 | $744,122 | 20,155 | Shares | Sole | 2025-05-16 | |
| 2024-12-31 | $38,594 | 1,159 | Shares | Sole | 2025-01-31 | |
| No filing history on record for this holder in this stock. | ||||||